Bioxytran Advances Multi-Platform Pipeline with ProLectin-M Under FDA IND and Oxygen Transport Programs
核心洞察
Bioxytran (搜索) completed a randomized, double-blind, placebo-controlled clinical trial for ProLectin-M in October 2025, with data expected to inform Phase 3 trial design and regulatory submissions.
The company continues developing its oxygen-transport platform including a universal oxygen carrier through a joint venture with the Heme Foundation (搜索) as an alternative to blood transfusions.
Bioxytran (搜索)'s galectin science research includes a cancer (搜索)-focused preprint exploring galectin-3 (搜索) modulation to improve immune checkpoint inhibitor response.
Bioxytran (搜索), Inc. (OTCQB:BIXT) has provided a comprehensive corporate update highlighting significant progress across its multi-platform pipeline, with particular emphasis on its lead antiviral program ProLectin-M operating under an active FDA Investigational New Drug (IND) framework and advancing oxygen-transport technologies for stroke (搜索) and neurodegenerative diseases (搜索).
ProLectin-M Antiviral Platform Advances
The company's flagship broad-spectrum antiviral program, ProLectin-M, reached a significant milestone in October 2025 with the completion of a randomized, double-blind, placebo-controlled clinical trial. According to the company, data from this trial is expected to help inform Phase 3 trial design and will be submitted to regulators pursuant to prior regulatory interactions.
Building on this progress, Bioxytran (搜索) completed dose optimization work in May 2025, which was specifically intended to support additional clinical trial planning and agency submissions. The ProLectin-M program continues to operate under the active FDA IND framework, positioning the company for continued regulatory advancement.
Oxygen Transport Platform Development
Bioxytran (搜索)'s oxygen-transport platform represents another key area of development, focusing on applications for stroke (搜索) and neurodegenerative diseases (搜索). The company continues advancing development efforts related to a universal oxygen carrier (UOC) and associated measurement and analytical approaches.
A notable strategic partnership was established in July 2024 when Bioxytran (搜索) announced a joint venture with the Heme Foundation (搜索) to develop a universal oxygen carrier as an alternative to blood transfusions. The collaboration includes public statements regarding pledged support levels and reported development progress.
The platform incorporates the use of the MDX Viewer, which the company describes as an FDA-approved device to measure tissue oxygenation, supporting the analytical framework for their oxygen transport research.
Oncology Research Through Galectin Science
In January 2025, Bioxytran (搜索) expanded its research portfolio by announcing a cancer (搜索)-focused preprint exploring galectin-3 (搜索) modulation as a potential strategy to improve response to immune checkpoint inhibitors. This research represents the company's application of galectin science to oncology applications.
Strategic Direction and Management Perspective
"Bioxytran (搜索) enters 2026 with real momentum across our platforms," said David Platt, Ph.D., Chief Executive Officer of Bioxytran. "Across virology and oxygen transport, our team has stayed focused on disciplined execution-building the data package, advancing the regulatory pathway, and expanding the scientific foundation that supports our programs. We believe our carbohydrate-based approach and galectin science position Bioxytran to pursue meaningful clinical and strategic opportunities as we continue to move forward."
Company Platform and Technology
Bioxytran (搜索) operates as a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design. The company's approach includes programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation.
The company's common stock trades on the OTCQB under the symbol BIXT, and it maintains its headquarters at 75 Second Avenue, Suite 605, Needham, MA 02494.